乙型肝炎相关性原发性肝癌发生的危险因素分析*

doi:10.3969/j.issn.1672-5069.2015.02.026

Abstract

Wu Chunxiao, Zhou Xiaolei, Chen Yanhong, et al.. Risk factors for occurrence of hepatocellular carcinoma in patients with chronic hepatitis B[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2015, 18(3): 306-307.

References

[1] Bard-Chapeau EA,Nguyen AT,Rust AG,et al. Transposon mutagenesis identifies genes driving hepatocellular carcinoma in a chronic hepatitis B mouse model. Nat Genet,2014,46（1）:24-32. [2] Duan F,Lam MG. Delivery approaches of gene therapy in hepatocellular carcinoma. Anticaer Res,2013,33（11）:4711-4718.
[3] 石虹,王吉耀,刘天舒,等. 慢性乙型肝炎患者血清生化指标与肝组织病理学炎症及纤维化程度的关系. 复旦学报（医学版）,2007,34（2）:246-249.
[4] 任海涛,李任飞,王月东. 原发性肝癌合并门静脉癌栓的治疗进展.介入放射学杂志,2013,22（11）:965-968.
[5] 中华医学会肝病学分会和感染病学分会. 慢性乙型肝炎防治指南（2010 年版）. 实用肝脏病杂志,2011,14（2）:81-89.
[6] 阮秀花,张效本,任丽君,等. 乙型肝炎病毒感染与原发性肝癌发生的关系.实用肝脏病杂志,2004,7（2）：130-132.
[7] Liu CJ,Kao JH. Global perspective on the natural history of chronic hepatitis B:role of hepatitis B virus genotypes A to J. Semin Liver Dis,2013,33（2）:97-102.
[8] Shin HJ,Park YH,Kim SU,et al. Hepatitis B virus X protein regulates hepatic glucose homeostasis via activation of inducible nitric oxide synthase. Biol Chem,2011,286（34）:29872-29881.
[9] Cho HK,Cheong KJ,Kim HY,et al. Endoplasmic reticulum stress induced by hepatitis B virus X protein enhances cyclo-oxygenase 2 expression via activating transcription factor 4. Biochem J,2011,435（2）:431-439.
[10] 邹长林,陈哲京,金文扬,等.温州地区原发性肝癌危险因素的病因分值及其交互效应.中华预防医学杂志,2003,37（5）：335.
[11] Saeki I,Terai S,Fujisawa K,et al. Bortezomib induces tumor-specific cell death and growth inhibition in hepatocellular carcinoma and improves liver fibrosis. Gastroenterology,2013,48（6）:738-750.
[12] Tsuchishima M,George J,Shiroeda H,et al. Chronic ingestion of ethanol induces hepatocellular carcinoma in mice without additional hepatic insult. Dig Dis Sci,2013,58（7）:1923-1933.
[13] 刘彦威,郭西平. 嗜酒对慢性乙型肝炎促发肝细胞癌危险因素的影响. 肝脏,2011,16（1）:84-85.
[14] 中华医学会肝病学分会肝癌学组.HBV/HCV相关性肝细胞癌抗病毒治疗专家建议. 实用肝脏病杂志,2013,16（2）:188-192.

[1]	Chen Shuai, Yang Changqing.. Pathogenesis and risk factors of portal vein thrombosis [J]. Journal of Practical Hepatology, 2019, 22(6): 761-764.
[2]	chronic hepatitis B Zhu Lingyun, Zhang Maohai Cui Shasha, et al.. Serum IL-12 and IL-18 levels as well as peripheral blood mononuclear cell FOXp3 in patients with [J]. Journal of Practical Hepatology, 2019, 22(6): 816-819.
[3]	Shi Yingying, Wang Yuanxi.. Impact of combination telbivudine and adefovir dipivoxil on renal functions in the treatment of patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(6): 820-823.
[4]	Min Feng, Huang Wenqi, Wu Weibing, et al.. Implications of serum adipocytokine levels in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(6): 824-827.
[5]	patients with chronic hepatitis B Zhang Yingming, Shen Shuang, Tian Fei, et al.. Prediction of response to peginterferon alfa-2a by blood IFNL4 and IL-28B gene polymorphisms in [J]. Journal of Practical Hepatology, 2019, 22(6): 828-831.
[6]	chronic hepatitis B virus carriers Wu Haiyi, Chen Jianxin.. Diagnostic efficacy of four non-invasive diagnostic models in evaluating significant liver fibrosis in [J]. Journal of Practical Hepatology, 2019, 22(6): 832-835.
[7]	Ma Liying, Shen Lijuan.. Efficacy and safety of tenofovir in the treatment of pregnant women with high HBV DNA loads [J]. Journal of Practical Hepatology, 2019, 22(6): 836-839.
[8]	Cao Ce, Yu Yixing, Wang Beibei, et al.. Clinical diagnostic efficacy of enhanced magnetic resonance imaging combined with serum AFP and PIVKA-Ⅱ in the diagnosis of patients with hepatocellular carcinoma [J]. Journal of Practical Hepatology, 2019, 22(6): 896-899.
[9]	Li Chuanjie, Xu Jing, Wang Liangliang, et al.. Changes of serum HBsAg levels in patients with chronic hepatitis B receiving entecavir treatment [J]. Journal of Practical Hepatology, 2019, 22(6): 928-929.
[10]	Xing Hao, Han Jun, Yang Tian.. Diagnostic value of serum protein induced by vitamin K absence or antagonist II for hepatocellular carcinoma [J]. Journal of Practical Hepatology, 2019, 22(6): 934-937.
[11]	Du Keye, Yang Dongliang, Liu Jia. Regulatory T cells in hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 613-616.
[12]	Liao Guichan, Peng Jie, Zhang Xiaoyong. Roles of hepatocytes in intrinsic innate immunity in control of hepatits B virus infection [J]. Journal of Practical Hepatology, 2019, 22(5): 617-619.
[13]	Zhao Xieshan, Wu Chunrong, Wang Chunfeng, et al. Preliminary study on the efficacy of combination of tenofovir and Anluo Huaxian pill in the treatment of patients with HBeAg-negative chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 644-647.
[14]	Tu Jiexia, Wang An’na, Liao Ruoxi. Comparative study of interferon alpha -2b and peginterferon alpha -2a in the treatment of patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 648-651.
[15]	Gao Wei, Hou Yong. Diagnostic efficacy of hepatic fibrosis by liver stiffness measurement in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 652-655.

Risk factors for occurrence of hepatocellular carcinoma in patients with chronic hepatitis B

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments